Superluminal raises $60 million to take an MC4R obesity drug into the clinic

Superluminal Medicines, a biotechnology company that uses AI and structural biology to design drugs, has closed a $60 million Series B financing round to advance an experimental obesity treatment into clinical testing ^[1]. The company says a Phase 1 trial of its lead drug candidate is expected to begin by the end of 2026 ^[1][2].

The drug targets a receptor called MC4R, short for melanocortin 4 receptor, which helps control appetite and how the body uses energy ^[1][2]. Superluminal describes its candidate as a "selective, biased" MC4R agonist, meaning it is designed to turn on only the specific signaling pathways tied to weight loss while leaving others alone, in hopes of reducing side effects ^[1]. In early laboratory studies, the company reported that the drug showed high selectivity and what it called a favorable safety profile ^[1].

The financing was led by BVF Partners, with new investors Deep Track Capital and Perceptive Advisors joining existing backers including RA Capital Management, Insight Partners, Nvidia, Catalio Capital Management, and Eli Lilly and Company ^[1]. Superluminal has now raised $213 million in venture funding since its founding ^[2]. The company also has an existing partnership with Eli Lilly to research other small-molecule drugs for cardiometabolic disease and obesity, targeting receptors that have not been disclosed ^[1][2].

The first planned use for the drug is in rare genetic conditions, including Bardet-Biedl syndrome and hypothalamic obesity, a form of obesity that can follow brain injury or tumor treatment ^[1][2]. Superluminal says the MC4R pathway could also eventually apply to Prader-Willi syndrome, another rare genetic condition, and even to general obesity if used alongside GLP-1 drugs ^[1]. Unlike Rhythm Pharmaceuticals' Imcivree (setmelanotide), which is already approved and given by injection for some of these same rare conditions, Superluminal's candidate is designed to be taken as a daily pill ^[2].

Why it matters for patients

Most GLP-1 drugs on the market today, such as Wegovy (semaglutide) and Zepbound (tirzepatide), work by different biological pathways and are not designed for people with rare genetic obesity disorders. For patients with conditions like Bardet-Biedl syndrome, treatment options remain limited, and MC4R-targeted drugs like Imcivree have been one of the few approved paths ^[2]. A new oral MC4R drug, if it succeeds in trials, could offer another option and potentially avoid the need for injections ^[2].

It is important to note this drug has not yet been tested in people. A Phase 1 trial, the earliest stage of human testing, is expected to start by the end of 2026, and such trials mainly check safety rather than prove a drug works ^[1][2]. Other companies pursuing MC4R and related rare-obesity biology have had mixed results: Neurocrine Biosciences markets Vykat XR for Prader-Willi syndrome, but a competing drug from Aardvark Therapeutics is on clinical hold, and one from Acadia Pharmaceuticals failed to meet its study goals ^[2]. Superluminal's CEO, Cony D'Cruz, said these experiences show that "efficacy alone is not enough" and that any new therapy needs to combine meaningful effects on weight and hunger with a safety profile that supports long-term use ^[2].

What happens next

Superluminal expects to begin a Phase 1 clinical trial of its MC4R drug candidate by the end of 2026 ^[1][2]. That trial would be an early safety study in a small number of people, and results would typically take time to become public. Whether the company pursues broader use in Prader-Willi syndrome or general obesity in combination with GLP-1 drugs will depend on how this first trial and future studies go ^[1][2].